Pull to refresh
Logo
FDA approves Gilead's Bixlenvo, a single-tablet option for HIV patients on complex regimens

FDA approves Gilead's Bixlenvo, a single-tablet option for HIV patients on complex regimens

New Capabilities

The pill pairs bictegravir with lenacapavir for virologically suppressed adults

Yesterday: FDA approves Gilead's Bixlenvo

Overview

Updated Yesterday

Roughly 5% of Americans living with HIV take their antiretrovirals as several pills a day, because resistance, side effects, or other medications rule out standard single tablets. On Thursday the FDA approved a pill built for that group.

Gilead's Bixlenvo combines bictegravir, the backbone of its blockbuster Biktarvy, with lenacapavir, a newer capsid inhibitor with no cross-resistance to other antiretrovirals. The 30-day list price is $4,595, and Gilead says the tablet is the smallest once-daily single-tablet HIV regimen yet.

Why it matters

The 5% of US HIV patients stuck on daily multi-pill regimens finally have a single-tablet option.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

$4,595
30-day list price before insurance discounts
In line with other daily HIV single tablets; Gilead offers free-drug assistance for uninsured patients.
5%
US adults with HIV on complex multi-tablet regimens
The population Bixlenvo is designed for, per Gilead.
48 weeks
Trial follow-up showing maintained viral suppression
Bixlenvo matched prior regimens at keeping the virus suppressed in both Phase 3 trials.
2%
Rate of most common side effects
Headache, nausea, and diarrhea, reported across the two ARTISTRY trials.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

March 2026 August 2026

2 events Latest: Yesterday
  1. FDA approves Gilead's Bixlenvo

    Latest Regulatory

    Agency clears the once-daily bictegravir/lenacapavir tablet, the first single-tablet regimen for HIV patients on complex multi-pill regimens.

  2. ARTISTRY-1 results published in The Lancet

    Research

    Phase 3 data show bictegravir plus lenacapavir maintains viral suppression at 48 weeks in virologically suppressed adults.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

July 2006

Atripla, the first once-daily HIV pill (2006)

The FDA approved Atripla, the first single-tablet HIV regimen, combining efavirenz, emtricitabine, and tenofovir. It collapsed what had been multi-pill 'cocktail' therapy into one daily tablet.

Then

Within a few years, once-daily single tablets became the default for most newly treated patients.

Now

The single-tablet era shifted HIV care from pill burden toward simplicity, setting the template Bixlenvo follows.

Why this matters now

Bixlenvo is the latest chapter in the same consolidation: shrinking complex regimens into one pill, this time for patients with drug resistance.

February 2018

Biktarvy launch (2018)

Gilead launched Biktarvy, a three-drug single tablet built on bictegravir. It became the most-prescribed HIV treatment in the US within a few years.

Then

Biktarvy set the standard for high-barrier, low-toxicity single tablets.

Now

Its success made bictegravir the workhorse backbone of Gilead's HIV franchise, which Bixlenvo now pairs with lenacapavir.

Why this matters now

Bixlenvo keeps bictegravir's proven profile but adds lenacapavir, targeting patients Biktarvy cannot serve.

Sources

(5)